Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Artiva Biotherapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- −6 vs. Q3 2025
- Shares held
- 17.0M
- −1.20M (−6.6%) vs. Q3 2025
- Total value
- $72.7M
- +$20.6M (+39.6%) vs. Q3 2025
- New holders
- 6
- 4 more added
- Sold out
- 12
- 15 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 72 | $391.6M |
| Q1 2026 | 40 | $108.4M |
| Q4 2025 | 34 | $72.7M |
| Q3 2025 | 40 | $52.1M |
| Q2 2025 | 48 | $27.9M |
| Q1 2025 | 53 | $62.8M |
| Q4 2024 | 57 | $213.2M |
| Q3 2024 | 49 | $319.4M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Artiva Biotherapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,853,302 | $42.3M | 0.43% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 2,353,304 | $10.1M | 3.17% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,609,569 | $6.91M | 0.34% | 00.0% | Unchanged |
| venBio Partners LLC | 648,507 | $2.78M | 1.29% | −500,468−43.6% | Reduced |
| Franklin Resources Inc | 520,327 | $2.23M | 0.00% | 00.0% | Unchanged |
| Revelation Capital Management, LLC | 299,311 | $1.28M | 1.54% | +299,311 | New |
| Vanguard Group Inc | 246,006 | $1.06M | 0.00% | +86,888+54.6% | Added |
| Millennium Management LLC | 217,097 | $931.3K | 0.00% | −45,063−17.2% | Reduced |
| BlackRock, Inc. | 212,538 | $911.8K | 0.00% | −81,884−27.8% | Reduced |
| Wellington Management Group LLP | 194,108 | $832.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 144,864 | $621.5K | 0.00% | +124,500+611.4% | Added |
| Renaissance Technologies LLC | 116,200 | $498.5K | 0.00% | +37,053+46.8% | Added |
| Geode Capital Management, LLC | 101,117 | $434.1K | 0.00% | −9,779−8.8% | Reduced |
| Alyeska Investment Group, L.P. | 100,000 | $429.0K | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 79,559 | $341.3K | 0.00% | +79,559 | New |
| Jane Street Group, LLC | 40,671 | $174.5K | 0.00% | +40,671 | New |
| UBS Group AG | 36,873 | $158.2K | 0.00% | +15,730+74.4% | Added |
| State Street Corp | 35,824 | $153.7K | 0.00% | −24,000−40.1% | Reduced |
| Bridgeway Capital Management, LLC | 35,000 | $150.2K | 0.00% | 00.0% | Unchanged |
| Scientech Research LLC | 27,757 | $119.1K | 0.07% | +27,757 | New |
| Morgan Stanley | 27,072 | $116.1K | 0.00% | −15,757−36.8% | Reduced |
| Omers Administration Corp | 21,100 | $90.5K | 0.00% | +21,100 | New |
| Goldman Sachs Group Inc | 12,060 | $51.7K | 0.00% | −37,717−75.8% | Reduced |
| Prelude Capital Management, LLC | 10,691 | $45.9K | 0.00% | −3,611−25.2% | Reduced |
| Russell Investments Group, Ltd. | 5,491 | $23.6K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 3,558 | $15.3K | 0.00% | −1,362−27.7% | Reduced |
| Wells Fargo & Company | 1,500 | $6.43K | 0.00% | −200−11.8% | Reduced |
| Tower Research Capital LLC (TRC) | 1,103 | $4.73K | 0.00% | −8,878−88.9% | Reduced |
| BNP Paribas Arbitrage, SA | 542 | $2.33K | 0.00% | −118,005−99.5% | Reduced |
| Mark Sheptoff Financial Planning, LLC | 400 | $1.72K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 339 | $1.00K | 0.00% | −501−59.6% | Reduced |
| JPMorgan Chase & Co | 187 | $802 | 0.00% | −3,815−95.3% | Reduced |
| Bank of America Corp | 113 | $484 | 0.00% | −16,032−99.3% | Reduced |
| Advisor Group Holdings, Inc. | 32 | $137 | 0.00% | +32 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −798,397−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −105,573−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −47,973−100.0% | Sold out |
| Landscape Capital Management, L.L.C. | 0 | $0 | 0.00% | −39,133−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −26,953−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −25,552−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −12,696−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −4,281−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −944−100.0% | Sold out |
| GF Fund Management Co. Ltd. | 0 | $0 | 0.00% | −510−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −159−100.0% | Sold out |
| Cloud Capital Management, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |